Memory and Aging Program, Butler Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Salloway, Stephen
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Recruiting
2
735
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
11/27
02/30
ARIAS, NCT03862222: Atlas of Retinal Imaging in Alzheimer's Study

Recruiting
N/A
330
US
Retinal Imaging, Pupillometry, Contrast Sensitivity, Neuropsychological Evaluation, APOE genotyping, blood draw, Gait Assessment, Timed Up and Go, Timed Up and Go - Dual Task (TUG, TUG-DT), Actigraphy
University of Rhode Island, Stuart Sinoff, MD, Peter J Snyder, MD, BayCare Health System
Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia, Aging, Cognitive Change
12/21
06/25
DIAN, NCT00869817: Dominantly Inherited Alzheimer Network

Recruiting
N/A
700
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, National Institute on Aging (NIA)
Alzheimer's Disease
07/25
07/25
POINTER, NCT03688126: U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk

Active, not recruiting
N/A
2000
US
Self-Guided Lifestyle Intervention, Self-Guided, Structured Lifestyle Intervention
Wake Forest University Health Sciences, Alzheimer's Association
Alzheimer Disease
07/25
07/25
NCT05457998: BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

Recruiting
N/A
200
US
Flutemetamol F18 Injection, Vizamyl, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
Butler Hospital, The Warren Alpert Foundation, Brown University, University of Rhode Island, Hoffmann-La Roche, Eli Lilly and Company, GE Healthcare
Alzheimer Disease, Mild Cognitive Impairment, Dementia
06/28
06/28
Riddle, Meghan
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Recruiting
3
800
Europe, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
06/24
05/25
ENVISION, NCT05310071: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Active, not recruiting
3
1512
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen
Alzheimer's Disease
12/25
10/26
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Recruiting
2
735
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
11/27
02/30
NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
LINE-AD, NCT04500847: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Recruiting
1
35
US
Emtriva Capsule, Emtricitabine, Placebo, Capsule manufactured to mimic Emtriva
Butler Hospital, Alzheimer's Association, Brown University, The Miriam Hospital
Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
03/24
03/24
LEADS, NCT03507257: Longitudinal Early-onset Alzheimer's Disease Study Protocol

Recruiting
N/A
700
US
Flortaucipir, 18F-AV-1451 (also known as [F-18]T807 or LY3191748), Florbetaben, AV-45, Neuraceq, Fluorodeoxyglucose, FDG
Indiana University, Alzheimer's Therapeutic Research Institute, National Institute on Aging (NIA), Alzheimer's Association
Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
05/24
05/24
ADNI3, NCT02854033: Alzheimer's Disease Neuroimaging Initiative 3

Recruiting
N/A
2000
Canada, US
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
07/24
07/24
ADNI4, NCT05617014: Alzheimer's Disease Neuroimaging Initiative 4

Recruiting
N/A
1500
Canada, US
Neuraceq, Florbetaben, Amyvid, Florbetapir, Tauvid, Flortaucipir, 18F-AV-1451, AV-1451, MK-6240, florquinitau F-18, [18F]MK-6240, NAV4694, [18F]NAV4694, [18F]AZD4694, PI-2620, [18F]PI-2620
University of Southern California, Northern California Institute of Research and Education, National Institute on Aging (NIA), Alzheimer's Therapeutic Research Institute
Mild Cognitive Impairment, Alzheimer Disease, Dementia
07/27
07/27
Sedivy, John
LINE-AD, NCT04500847: Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Recruiting
1
35
US
Emtriva Capsule, Emtricitabine, Placebo, Capsule manufactured to mimic Emtriva
Butler Hospital, Alzheimer's Association, Brown University, The Miriam Hospital
Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
03/24
03/24

Download Options